sulfinpyrazone


Also found in: Dictionary, Wikipedia.

sulfinpyrazone

 [sul″fin-pi´rah-zōn]
a uricosuric compound used in gout to promote excretion of uric acid; administered orally. It also prolongs platelet survival and inhibits platelet adherence to subendothelial cells and prostaglandin synthesis and has been studied as an antithrombotic agent.

sulfinpyrazone

/sul·fin·py·ra·zone/ (sul″fin-pi´rah-zōn) a uricosuric agent used in the treatment of gout.

sulfinpyrazone

(sŭl′fĭn-pĭr′ə-zōn′)
n.
A drug, C23H20N2O3S, related to phenylbutazone, that promotes urinary excretion of uric acid and is used in the treatment of gout.

sulfinpyrazone

[sul′finpir′əzōn]
a uricosuric drug.
indications It is prescribed in the treatment of chronic gout and intermittent gouty arthritis.
contraindications Peptic ulcer, ulcerative colitis, renal dysfunction, or known hypersensitivity to this drug or to phenylbutazone prohibits its use. It is not usually given during an acute attack of gout.
adverse effects Among the more serious adverse effects are GI ulcers, blood dyscrasias, and dermatitis.

Sulfinpyrazone

A drug that corrects hyperuricemia by increasing the urinary excretion of urate.
Mentioned in: Gout

sulfinpyrazone

uricosuric agent used as an alternative to allopurinol in the long-term management of tophaceous gout

sulfinpyrazone (sul´finpir´əzōn´),

n brand name: Anturane;
drug class: uricosuric;
action: inhibits tubular reabsorption of urates, with increased excretion of uric acid; inhibits prostaglandin synthesis, which decreases platelet aggregation;
use: treatment of chronic gouty arthritis.
References in periodicals archive ?
49) Note: Related drugs included aspirin, sulfinpyrazone, and ticlopidine.
The AWP of a month supply of brand name (Anturane) and generic sulfinpyrazone in 1991 was $48.
Sulfinpyrazone use is problematic, given its side effects and drug interactions, and sulfinpyrazone is not universally available.
13) Unequivocally, benzbromarone, probenecid, losartan, sulfinpyrazone, and high doses of salicylates elevate uricosuric activity primarily through inhibition of URAT1.
Underexcretion hyperuricemia; and allergy, intolerance, or contraindications to both probenecid and sulfinpyrazone.
The following drugs may increase the effectiveness of insulin, resulting in hypoglycemia: ACE inhibitors, alcohol, anabolic steroids, beta blockers, calcium, chloroquine, clofibrate, clonidine, disopyramide, fluoxetine, guanethidine, lithium, mebendazole, monoamine oxidase inhibitors, octreotide, pentamidine, phenylbutazone, propoxyphene, pyridoxine, salicylates, sulfinpyrazone, sulfonamides, and tetracyclines.
Drugs such as trimethoprim-sulfathiazole (TMP-sulfa), erythromycin, cimetidine, metronidazole, ketoconazole, fluconazole, itraconazole, amiodarone, and sulfinpyrazone all decrease the warfarin metabolism, which can increase prothrombin times and raise the international normalized ratio (INR).
2] antagonists, magnesium salts, methyldopa, monoamine oxidase inhibitors, probenecid, salicylates, sulfinpyrazone, sulfonamides, tricyclic antidepressants, and urinary acidifiers.
Hepatotoxicity be increased with long-term combined use with barbiturates (such as phenobarbital), carbamazepine, hydantoins (such as phenytoin), isoniazid, rifampin, and sulfinpyrazone.